GENMAB A/S's ticker is GMAB and the CUSIP is 372303206. A total of 131 filers reported holding GENMAB A/S in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,859 | +15.2% | 478 | +24.2% | 0.00% | +50.0% |
| Q2 2023 | $14,634 | +10.1% | 385 | +9.4% | 0.00% | 0.0% |
| Q1 2023 | $13,292 | -29.0% | 352 | -20.4% | 0.00% | -33.3% |
| Q4 2022 | $18,732 | +87.3% | 442 | +42.1% | 0.00% | +50.0% |
| Q3 2022 | $10,000 | +150.0% | 311 | +150.8% | 0.00% | +100.0% |
| Q2 2022 | $4,000 | -50.0% | 124 | -43.9% | 0.00% | 0.0% |
| Q1 2022 | $8,000 | 0.0% | 221 | +4.2% | 0.00% | 0.0% |
| Q4 2021 | $8,000 | +60.0% | 212 | +73.8% | 0.00% | 0.0% |
| Q3 2021 | $5,000 | +25.0% | 122 | +22.0% | 0.00% | 0.0% |
| Q2 2021 | $4,000 | +300.0% | 100 | +203.0% | 0.00% | – |
| Q1 2021 | $1,000 | -91.7% | 33 | -88.2% | 0.00% | -100.0% |
| Q4 2020 | $12,000 | +500.0% | 280 | +522.2% | 0.00% | 0.0% |
| Q3 2020 | $2,000 | +100.0% | 45 | +150.0% | 0.00% | – |
| Q2 2020 | $1,000 | – | 18 | +50.0% | 0.00% | – |
| Q1 2020 | $0 | – | 12 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 12 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 242,848 | $9,169,940 | 3.80% |
| Capricorn Fund Managers Ltd | 110,643 | $4,177,880 | 1.28% |
| Arlington Capital Management, Inc. | 35,591 | $1,343,916 | 1.26% |
| XY Capital Ltd | 76,884 | $2,903,140 | 1.13% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 88,000 | $3,322,880 | 0.93% |
| TORRAY INVESTMENT PARTNERS LLC | 110,807 | $4,184,072 | 0.75% |
| Hardman Johnston Global Advisors LLC | 585,139 | $22,094,849 | 0.72% |
| Yorktown Management & Research Co Inc | 16,600 | $626,816 | 0.68% |
| First Light Asset Management, LLC | 160,025 | $6,042,544 | 0.54% |
| MIRABELLA FINANCIAL SERVICES LLP | 28,260 | $2,505,855 | 0.38% |